Nordic Capital offers to buy Advanz Pharma in $846 million deal
Jan 27 (Reuters) – Private equity investor Nordic Capital on Wednesday offered to buy Advanz Pharma, valuing the drugmaker at $846 million as part of a move to invest in accelerating the company’s pipeline of innovative specialty pharmaceutical products.
Under the offer, shareholders would receive a price of $17.26 per Advanz Pharma share and can also elect a non-cash alternative offer to receive unlisted shares in Cidron Aida for each Advanz Pharma share. (Reporting by Tanishaa Nadkar in Bengaluru; Editing by Arun Koyyur)
